Despite the inherently wide margin of safety for ingredients typically found in dietary supplements, manufacturing and quality issues can arise and other unexpected safety issues can emerge. Even when companies put robust safety surveillance systems in place to monitor the quality and safety of their products, the data that is generated can sometimes be misinterpreted and further confuse the issue. Rick Kingston, President, Regulatory and Scientific Affairs of SafetyCall International, along with presenters from the FDA, industry and academia, will discuss issues and opportunities surrounding regulatory compliance, safety surveillance and risk assessment for dietary supplements at the 11th Annual Oxford International Conference on the Science of Botanicals, April 16-19, 2012, at the University of Mississippi in Oxford, Mississippi.
Prweb.com: Bloomington, MN (PRWEB) April 06, 2012
Inherent differences between the way drugs and dietary supplements are marketed and used by consumers gives rise to distinct difference in the way they are monitored in the marketplace for quality and safety.
In the case of drugs, safety surveillance is carried out at multiple levels. Drug manufacturers receive information from a variety of sources which typically includes published medical literature, ongoing clinical trials, multi-center studies and communications from those professionals that prescribe and otherwise monitor the safe and effective use of drugs in their patients. Read More